Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 50228-121

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 50228-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure11 (Clopidogrel 300mg 30tab)

Label for Clopidogrel tablets, USP, 300 mg strength, oral film-coated tablets. The label indicates a package size of 30 tablets and is manufactured by ScieGen Pharmaceuticals Inc, Hauppauge, NY. Includes storage instructions and a barcode with NDC 50228-121-30.*

FDA Label Image

Figure12 (Clopidogrel 300mg 500tab)

Clopidogrel tablets, USP 300 mg film-coated oral tablets label by ScieGen Pharmaceuticals Inc. The label includes dosage information specifying each tablet contains 391.5 mg clopidogrel bisulfate equivalent to 300 mg clopidogrel base. The package contains 500 tablets. Storage instructions are provided, along with the NDC 50228-121-05 and barcode.*

FDA Label Image

Container (Clopidogrel 75mg 1000tab)

Clopidogrel tablets USP 75 mg film-coated oral tablets label by ScieGen Pharmaceuticals Inc. The label indicates each tablet contains clopidogrel bisulfate equivalent to 75 mg clopidogrel base. The package contains 1,000 tablets and is marked Rx only. Storage instructions and manufacturer details are also included.*

FDA Label Image

Container (Clopidogrel 75mg 30tab)

Label for Clopidogrel tablets, USP 75 mg oral film-coated tablets by ScieGen Pharmaceuticals Inc. The package contains 30 tablets. The label includes storage instructions, dosage guidance referencing accompanying information, and a barcode. It states the active ingredient amount as 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base, with a pharmacist instruction to dispense the medication guide.*

FDA Label Image

Container05 (Clopidogrel 75mg 500tab)

Label for Clopidogrel Tablets, USP 75 mg, oral film-coated tablets. The label states each tablet contains clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It includes storage instructions, pharmacist dispensing directions, and the labeler ScieGen Pharmaceuticals Inc. The package holds 500 tablets for prescription use only, with NDC 50228-124-05 and a barcode.*

FDA Label Image

Container90 (Clopidogrel 75mg 90tab)

Label for Clopidogrel bisulfate tablets, USP, 75 mg strength, film-coated oral tablets. The label indicates 90 tablets per package, with manufacturer ScieGen Pharmaceuticals Inc. Dosage form and pharmacist dispensing instructions are included. The label features a barcode and storage temperature guidelines.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A forest plot showing the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite AUC of Clopidogrel 75 mg. The plot displays mean values with 90% confidence intervals, illustrating changes relative to Clopidogrel administered alone.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. Two lines compare placebo (+ aspirin) and clopidogrel (+ aspirin) groups, with the clopidogrel group showing lower event rates. A statistical significance value (P=0.00009) is noted, and a footnote mentions other standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

Two forest plots displaying subgroup analyses comparing Clopidogrel bisulfate versus placebo. The plots show hazard ratios with 95% confidence intervals for various subgroups categorized by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The overall hazard ratio favors Clopidogrel bisulfate with detailed counts and percentages for each subgroup in both treatment and placebo groups.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A line graph titled 'Figure 4: Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of deaths before first discharge over days since randomization, up to 28 days. It compares death rates between placebo (8.1%) and Clopidogrel (7.5%), indicating a 7% proportional risk reduction with Clopidogrel. The graph includes stepwise lines representing the cumulative percentage of deaths for each group.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A cumulative event curve chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. It compares two groups: Placebo (10.1% event rate in 2310 patients) and Clopidogrel (9.2% event rate in 2121 patients), highlighting a 9% proportional risk reduction for Clopidogrel with a p-value of 0.002.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot showing the effects of adding Clopidogrel to Aspirin on the combined primary endpoint in different medication subgroups from the COMMIT study. The chart compares Clopidogrel and placebo groups across subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, depicting odds ratios with 99% confidence intervals.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph depicting the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up. Two lines compare the rates for Aspirin and Clopidogrel, with Clopidogrel showing a slightly lower event rate. The x-axis represents months of follow-up, and the y-axis represents cumulative event rate percentage. A p-value of 0.045 is shown, indicating statistical comparison between the two lines.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot illustrating hazard ratios and 95% confidence intervals by baseline subgroups in the CAPRIE study comparing Clopidogrel and Aspirin. It presents data for stroke, MI, PAD, and overall, showing the number and percentages of events for Clopidogrel and Aspirin groups on a horizontal axis labeled Hazard Ratio (95% CI) ranging from 0.6 to 1.3, with reference lines favoring Clopidogrel or Aspirin.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of Clopidogrel bisulfate, showing the molecular arrangement including a thienopyridine ring, methyl ester, chlorine-substituted phenyl ring, and associated sulfuric acid molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.